Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease

Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation

(2023) Neda Yahoo et al.   JOURNAL OF HEPATOLOGY

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

(2022) Ghassan K. Abou-Alfa et al.   JOURNAL OF CLINICAL ONCOLOGY

Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease

(2022) Katharina Staufer et al.   JOURNAL OF HEPATOLOGY

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

(2022) Robin Kate Kelley et al.   LANCET ONCOLOGY

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

(2022) R.S. Finn et al.   ANNALS OF ONCOLOGY

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

(2021) Zhenggang Ren et al.   LANCET ONCOLOGY

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

(2021) Ann-Lii Cheng et al.   JOURNAL OF HEPATOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

(2012) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY